Clinical Trials
Below are current clinical trials.
272 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The purpose of this study is to establish whether therapeutic-dose parenteral anticoagulation improves outcomes (reduces intubation or mortality) by 30 days after randomization.
-
Rochester, Minn.
Staphylococcus aureus is responsible for at least 20% of the healthcare associated blood stream infections in the United States. One of the most worrisome complications of S. aureus bacteremia (SAB) is infective endocarditis (IE).Our goal from this project is to prospectively validate the Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT) scoring system and to assess the potential novel risk factors to optimize the PREDICT scoring system prior to formal implementation in clinical practice.
-
Rochester, Minn.
The purpose of this study is to determine the sensitivity, specificity, positive and negative predictive values of molecular detection of microorganisms, detection of microbial proteins and antibodies against microorganisms, and inflammatory markers (e.g., leukocyte esterase, CRP) in synovial fluid for the diagnosis of prosthetic joint infection (PJI).
-
Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to generate evidence demonstrating the domain specification (via modern psychometric methods), reliability, validity, and responsiveness (within-subject meaningful change) of the patient-reported outcome (PRO) endpoints.
-
Rochester, Minn.
The purpose of this study is to determine whether short-term treatment with Fisetin reduces the rate of death and long term complications related to COVID-19.
-
Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.
The study seeks to understand the impacts the COVID pandemic has brought to the communities, how communities are coping and how we can build resilience to prepare future health crises.
-
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.
-
Rochester, Minn.
The purpose of this study is to determine the percentage of patients at moderate risk for infective endocarditis (IE) who are receiving antibiotic prophylaxis post-2007 in Olmsted County, Minnesota.
-
Eau Claire, Wis., Rochester, Minn.
The primary objective of Aim 1 of this study are to identify personal and social determinant of health-related key factors that present as a barriers to use of non-emergent telehealth care during the COVID-19 pandemic. Aim 1 will use a qualitative study design to understand the experiences of patients along with social determinants of health (SDOH). The results of the qualitative work will be used by the research team to design the survey for administration in Aim 2.
The primary objectgive of Aim 2 of this study is to assess personal and social determinants of health that are associated with patient’s decision to prefer face-to-face visits compared with telehealth appointments for non-emergent care.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to determine whether adding clofazimine in a treatment regimen for patients with non-tuberculous mycobacterial (NTM) infections will improve low clinical success rates in NTM infections, its mode of action, and literature reported clinical data in both NTM and multidrug-resistant tuberculosis.